SOFIVA Genomics, a leading brand in genetic testing, today announced an operating revenue of NTD $45.27 million in June and a record-high consolidated Q2 operating revenue of NTD $133 million, achieving an accumulated operating revenue of NTD $258 million and a year-to-date growth of 6.46%. Chia-Cheng Hung, General Manager of SOFIVA, expressed, “With the recent implementation of expanded IVF subsidies and policies, IVF-related testing demands are on the rise, which is expected to boost the sales of niPGS, a product we launched earlier this year.“

NIPS Sales Continue to Grow as SOFIVA’s Performance Rises
According to the Ministry of the Interior’s statistics, Taiwan’s population exhibited a negative growth for the first time in 2020. The total number of newborns in January 2021 fell below 10,000 for the first time. In the face of a decreasing birth rate, Chia-Cheng Hung, General Manager of SOFIVA, stated that “Although Taiwan’s birth rate is decreasing by the year, we’ve observed that expecting couples have a heightened awareness of their health and the health of their unborn child. We’ve observed a significant increase in the number of pregnant women seeking genetic testing. During the first half of this year, the overall sales of SOFIVA’s NIPS product grew significantly, which has also boosted SOFIVA’s recent revenue. As expecting couples place an increasing emphasis on prenatal screening and fetal health, market demand for NIPS and Carrier Scan will rise.”

Expanded IVF Policies Hit the Road in July; PGS Demands Projected to Rise
To address Taiwan’s low birthrate, the government officially implemented a subsidy program for infertility treatment (IVF) on July 1. This policy is expected to benefit 23,000-28,000 couples per year. The number of IVF babies exceeded 10,000 in 2018, and this number is likely to further increase following the rollout of the new policy.

To qualify for the subsidy, women under 35 may have no more than one embryo transfer, whereas women aged between 36 and 44 may have two. Thus, women seeking IVF treatment will place a greater emphasis on embryo health. Chia-Cheng Hung, General Manager of SOFIVA, reiterates that “The IVF subsidy policy limits the number of embryos that may be transferred based on the mother’s age. PGS is a process that helps identify healthy embryos, which increases the IVF success rate. We have received many recent inquiries about relevant products and subsidy programs, and we’re optimistic about this new policy, which is sure to promote the development of the IVF market and further boost Taiwan’s birthrate.”